| Note | |
| | |
| Entity | Colon cancer |
| Note | CEACAM1 mRNA was demonstrated to be down-regulated to < or = 0.4 in 80% of 21 colorectal carcinoma tissue specimens as compared with the respective adjacent normal mucosa (Neumaier et al., 1993). CEACAM1 was reported to be associated with pp60c-src, suggesting that down-regulation of CEACAM1 in about 80% of colorectal carcinomas may contribute to a dysfunction of pp60c-src in colorectal cancer (Brummer et al., 1995). |
| | |
| | |
| Entity | Hepatocellular carcinoma |
| Note | CEACAM1 was reported to be diffusely expressed in 113 of 139 hepatomas. Loss of CEACAM1 expression was closely associated with large tumor size, multiplicity of the tumor, portal vein invasion, and satellite nodules and affected survival adversely, according to univariate (P < 0.0001) and multivariate analyses (relative risk, 5.737; P < 0.001) (Cruz et al., 2005). In rat hepatoma cells 1682A, restoration of CEACAM1-4L expression was demonstrated to completely suppress the tumor formation (Laurie et al., 2005). In human hepatoma cell lines (HLF, PLC/PRF/5, HepG2 and KYN-2), CEACAM1 protein was demonstrated to only express in HepG2, which shows a strong property for enhanced anchorage-independent growth. It was reported that CEACAM1 acts as a tumor suppressor when the cells are cultured in anchorage-dependent growth conditions. In contrast, in anchorage-independent growth conditions, CEACAM1 augments cell proliferation by potentiating the cell-cell attachment (Hokari et al., 2007). |
| | |
| | |
| Entity | Breast cancer |
| Note | CEACAM1 is down-regulated in around 30% of breast cancers. CEACAM1 is reported to suppress the tumorigenicity of breast cancer cells via its cytoplasmic domain but not the extracellular domain (Luo et al., 1997). CEACAM1 is demonstrated to be consistently expressed in normal tissue and benign lesions of mammary gland, whereas it disappears with the development of the malignant phenotype in both noninvasive and invasive carcinoma (Riethdorf et al., 1997). CEACAM1 is reported to be expressed at high levels in cribiform ductal carcinoma in situ (DCIS). Although most invasive ductal carcinomas express CEACAM1 weakly, tumours with minimal lumena formation show cytoplasmic CEACAM1 expression (Kirshner et al., 2004). |
| | |
| | |
| Entity | Prostate cancer |
| Note | CEACAM1 is reported to be regulated by androgen and might act as a growth repressor during differentiation of the prostatic epithelium. Forced expression of CEACAM1 results in the significantly lower growth rates of human prostatic cancer cell line PC-3 (Hsieh et al., 1995). |
| | |
| | |
| Entity | Bladder cancer |
| Note | CEACAM1 is expressed in umbrella cells of bladder urothelium, but is down-regulated in superficial bladder cancer. CEACAM1 silencing in bladder cancer cell lines 486p and RT4 using the small interfering RNA technique leads to a significant up-regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D, suggesting that the epithelial down-regulation of CEACAM1 induces angiogenesis via increased expression of VEGF-C and VEGF-D (Oliveira-Ferrer et al., 2004). |
| | |
| | |
| Entity | Melanoma |
| Note | A total of 28 of 40 patients with CEACAM1-positive primary melanomas developed metastatic disease, compared with only six of 60 patients with CEACAM1-negative melanomas. the strongest CEACAM1 expression was observed at the invading front. Kaplan-Meier analysis revealed a highly significant association between CEACAM1 expression and metastasis (P <.0001) (Thies et al., 2002). |
| | |
| | |
| Entity | Renal cell carcinoma |
| Note | In normal kidney, CEACAM1 was found in epithelial cells of proximal tubules and in endothelial cells. In contrast, tumour cells of 30 clear cell, three chromophobic, and two chromophilic RCCs were completely devoid of CEACAM1. Renal adenomas also lacked CEACAM1 expression. Similarly, RCC cell lines CaKi1, CaKi2, A498, and RCC26 exhibited no or low-level CEACAM1 expression. However, CEACAM1 expression was transiently induced in A498 cells upon contact with allogeneic CD8+ T cells, mediated at least in part by interferon-gamma. Furthermore, the majority of tumour-infiltrating T and NK cells expressed CEACAM1 upon stimulation. Thus, transient expression of the tumour suppressor CEACAM1 by tumour cells and subsequent homophilic interaction with CEACAM1 on tumour-infiltrating lymphocytes could represent a novel immune escape mechanism in RCC (Kammerer et al., 2004). |
| | |
| CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation. |
| Abou-Rjaily GA, Lee SJ, May D, Al-Share QY, Deangelis AM, Ruch RJ, Neumaier M, Kalthoff H, Lin SH, Najjar SM. |
| J Clin Invest. 2004 Oct;114(7):944-52. |
| PMID 15467833 |
| |
| Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas. |
| Brummer J, Neumaier M, Gopfert C, Wagener C. |
| Oncogene. 1995 Oct 19;11(8):1649-55. |
| PMID 7478590 |
| |
| Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma. |
| Cruz PV, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K. |
| Cancer. 2005 Jul 15;104(2):354-60. |
| PMID 15952183 |
| |
| CEACAM1: contact-dependent control of immunity. |
| Gray-Owen SD, Blumberg RS. |
| Nat Rev Immunol. 2006 Jun;6(6):433-46. (REVIEW) |
| PMID 16724098 |
| |
| Tumor suppressor carcinoembryonic antigen-related cell adhesion molecule 1 potentates the anchorage-independent growth of human hepatoma HepG2 cells. |
| Hokari M, Matsuda Y, Wakai T, Shirai Y, Sato M, Tsuchiya A, Takamura M, Yamagiwa S, Suzuki K, Ohkoshi S, Ichida T, Kawachi H, Aoyagi Y. |
| Life Sci. 2007 Jul 4;81(4):336-45. Epub 2007 Jun 16. |
| PMID 17612570 |
| |
| Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. |
| Horst AK, Ito WD, Dabelstein J, Schumacher U, Sander H, Turbide C, Brummer J, Meinertz T, Beauchemin N, Wagener C. |
| J Clin Invest. 2006 Jun;116(6):1596-605. Epub 2006 May 4. |
| PMID 16680193 |
| |
| Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. |
| Hsieh JT, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin SH. |
| Cancer Res. 1995 Jan 1;55(1):190-7. |
| PMID 7805032 |
| |
| The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma. |
| Kammerer R, Riesenberg R, Weiler C, Lohrmann J, Schleypen J, Zimmermann W. |
| J Pathol. 2004 Nov;204(3):258-67. |
| PMID 15476270 |
| |
| Cell-cell adhesion molecule CEACAM1 is expressed in normal breast and milk and associates with beta1 integrin in a 3D model of morphogenesis. |
| Kirshner J, Hardy J, Wilczynski S, Shively JE. |
| J Mol Histol. 2004 Mar;35(3):287-99. (REVIEW) |
| PMID 15339048 |
| |
| Hepatocellular carcinoma, adenoma, and focal nodular hyperplasia. Comparative histopathologic study with immunohistochemical parameters. |
| Koelma IA, Nap M, Huitema S, Krom RA, Houthoff HJ. |
| Arch Pathol Lab Med. 1986 Nov;110(11):1035-40. |
| PMID 2430547 |
| |
| CEACAMs: their role in physiology and pathophysiology. |
| Kuespert K, Pils S, Hauck CR. |
| Curr Opin Cell Biol. 2006 Oct;18(5):565-71. Epub 2006 Aug 17. (REVIEW) |
| PMID 16919437 |
| |
| Carcinoembryonic antigen-related cell adhesion molecule 1a-4L suppression of rat hepatocellular carcinomas. |
| Laurie NA, Comegys MM, Carreiro MP, Brown JF, Flanagan DL, Brilliant KE, Hixson DC. |
| Cancer Res. 2005 Dec 1;65(23):11010-7. |
| PMID 16322250 |
| |
| Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. |
| Luo W, Wood CG, Earley K, Hung MC, Lin SH. |
| Oncogene. 1997 Apr 10;14(14):1697-704. |
| PMID 9135071 |
| |
| Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. |
| Neumaier M, Paululat S, Chan A, Matthaes P, Wagener C. |
| Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10744-8. |
| PMID 7504281 |
| |
| Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. |
| Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Kilic E, Huland H, Friedrich M, Ergun S. |
| Cancer Res. 2004 Dec 15;64(24):8932-8. |
| PMID 15604255 |
| |
| CEACAM1 regulates insulin clearance in liver. |
| Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, Erickson SK, Najjar SM. |
| Nat Genet. 2002 Mar;30(3):270-6. Epub 2002 Feb 19. |
| PMID 11850617 |
| |
| Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. |
| Riethdorf L, Lisboa BW, Henkel U, Naumann M, Wagener C, Loning T. |
| J Histochem Cytochem. 1997 Jul;45(7):957-63. |
| PMID 9212821 |
| |
| CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells. |
| Slevogt H, Zabel S, Opitz B, Hocke A, Eitel J, N'guessan PD, Lucka L, Riesbeck K, Zimmermann W, Zweigner J, Temmesfeld-Wollbrueck B, Suttorp N, Singer BB. |
| Nat Immunol. 2008 Nov;9(11):1270-8. Epub 2008 Oct 5. |
| PMID 18836450 |
| |
| CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. |
| Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, Brunner G, Schumacher U. |
| J Clin Oncol. 2002 May 15;20(10):2530-6. |
| PMID 12011132 |
| |
| Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. |
| Wagener C, Ergun S. |
| Exp Cell Res. 2000 Nov 25;261(1):19-24. (REVIEW) |
| PMID 11082271 |
| |